To test the hypothesis that TH-302 would complement antiangiogenic therapy, we used the hypoxia-activated prodrug TH-302 and an antibody targeting VEGFR-2, which can transiently improve tumor oxygenation and normalize tumor vasculature (16). This evidence concerns the gene KDR and neoplasm.